Compare TWAV & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWAV | CDT |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | 7 | 4 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | TWAV | CDT |
|---|---|---|
| Price | $1.59 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.37 |
| 52 Week High | $2.58 | $11.00 |
| Indicator | TWAV | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 33.11 |
| Support Level | $1.29 | $0.49 |
| Resistance Level | $1.86 | $0.73 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 24.22 | 1.11 |
TaoWeave Inc is a digital asset company. The company offers investors a regulated, publicly traded vehicle to gain exposure to the decentralized AI economy. The company aims to invest in the Bittensor ecosystem through partnerships with subnets, miners, and validators, and operates with zero debt by maintain appropriate cash reserves. The Company currently operates in three segments: (1) "Digital Assets", which represents the business surrounding treasury activity with Bittensor, (2) Collaboration Products which represents the business surrounding Mezzanine product offerings, and (3) Managed Services, which represents the business surrounding managed services for video collaboration and network solutions.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.